Reed S E, Craig J W, Tyrrell D A
J Infect Dis. 1976 Jun;133 Suppl:A128-35. doi: 10.1093/infdis/133.supplement_2.a128.
Four unrelated compounds active against rhinovirus were compared in tissue culture, and three of them were used in volunteers challenged with rhinovirus. The compounds were the triazino-indole SKF 40491, the substituted oxadiazole GLR9-338, the imidazo-thiazole RP L9326, and the guanidine derivative ICI 73,602. The abilities of these compounds to reduce the yield of rhinovirus types 3, 4, 9, and 31 from HeLa cells or fibroblasts were compared, and a sensitive serotype was chosen for each challenge experiment in humans. In doubleblind studies volunteers received intranasal medication before and after the challenge. Daily scoring of symptoms and titration of virus in nasal washings showed that subjects treated with SKF, GL, and RP all shed less virus than their corresponding placebo groups, significantly so in the cases of GL and RP. Clinical reactions were also less severe in volunteers treated with RP.
在组织培养中对四种抗鼻病毒的不相关化合物进行了比较,其中三种用于感染鼻病毒的志愿者。这些化合物分别是三嗪并吲哚SKF 40491、取代恶二唑GLR9 - 338、咪唑并噻唑RP L9326和胍衍生物ICI 73,602。比较了这些化合物降低HeLa细胞或成纤维细胞中3型、4型、9型和31型鼻病毒产量的能力,并为每项人体激发实验选择了一种敏感血清型。在双盲研究中,志愿者在激发前后接受鼻内用药。对症状的每日评分和鼻洗液中病毒的滴定显示,接受SKF、GL和RP治疗的受试者排出的病毒比相应的安慰剂组少,GL和RP组的情况尤为显著。接受RP治疗的志愿者的临床反应也较轻。